{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.1","upperLimit":"15.1","value":"11.4"},{"comment":"Upper limit of 95% confidence interval (CI) was not estimable due to the smaller number of participants with events.","groupId":"OG001","lowerLimit":"5.5","upperLimit":"NA","value":"11.8"},{"comment":"Upper limit of 95% CI was not estimable due to the smaller number of participants with events.","groupId":"OG002","lowerLimit":"2.1","upperLimit":"NA","value":"8.6"},{"comment":"Upper limit of 95% CI was not estimable due to the smaller number of participants with events.","groupId":"OG003","lowerLimit":"4.6","upperLimit":"NA","value":"5.8"},{"comment":"Upper limit of 95% CI was not estimable due to the smaller number of participants with events.","groupId":"OG004","lowerLimit":"6.7","upperLimit":"NA","value":"10.5"},{"comment":"Upper limit of 95% CI was not estimable due to the smaller number of participants with events.","groupId":"OG005","lowerLimit":"5.6","upperLimit":"NA","value":"7.2"},{"comment":"Median and upper limit of 95% CI was not estimable due to the smaller number of participants with events.","groupId":"OG006","lowerLimit":"12.2","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"34"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"27"},{"groupId":"OG006","value":"27"}],"units":"Participants"}],"description":"An OS was defined as the time (in months) from the date of the first dose to the death date. In the absence of death confirmation or for participants alive as of the OS cut-off date, survival time was censored at the date of last study follow-up, or the cut-off date, whichever was earlier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with intra-hepatic or extrahepatic cholangiocarcinoma (iCCA or eCCA) harboring FGFR2 gene fusions or rearrangements and who were treated or not treated with prior FGFR inhibitors received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG000","title":"Phase 1: Dose Expansion Cohort 1"},{"description":"Participants with primary central nervous system (CNS) tumors harboring FGFR gene fusions or FGFR1 activating mutations received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG001","title":"Phase 1: Dose Expansion: Cohort 2"},{"description":"Participants with advanced urothelial carcinoma harboring FGFR3 gene fusions or FGFR3 activating mutations received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG002","title":"Phase 1: Dose Expansion: Cohort 3"},{"description":"Participants with breast or gastric cancer with harboring FGFR2 amplification received TAS-120 20 mg tablets orally QD in each of 21- day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG003","title":"Phase 1: Dose Expansion: Cohort 4"},{"description":"Participants with tumor types harboring FGFR gene fusions or activating mutations received TAS-120 20 mg tablets orally QD in each of 21- day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG004","title":"Phase 1: Dose Expansion: Cohort 5"},{"description":"Participants who were not included in Cohorts 1 to 5 received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG005","title":"Phase 1: Dose Expansion: Cohort 6"},{"description":"Participants with iCCA and other tumor types who were enrolled prior to the confirmation of the RP2D received TAS-120 16 mg tablets orally QD in each of 21- day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG006","title":"Phase 1: Dose Expansion: Pooled Sub-cohort"}],"paramType":"MEDIAN","populationDescription":"Efficacy population included all participants who had received at least 1 dose of TAS-120. Data was planned to be collected and analyzed on pooled population of participants who received 16 mg of TAS-120 in the sub-cohorts 1 and 2.","reportingStatus":"POSTED","timeFrame":"up to approximately 27.5 months (through cut-off date 30-Jun-2019)","title":"Phase 1: Dose Expansion: Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}